[go: up one dir, main page]

CL2018001199A1 - Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana - Google Patents

Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana

Info

Publication number
CL2018001199A1
CL2018001199A1 CL2018001199A CL2018001199A CL2018001199A1 CL 2018001199 A1 CL2018001199 A1 CL 2018001199A1 CL 2018001199 A CL2018001199 A CL 2018001199A CL 2018001199 A CL2018001199 A CL 2018001199A CL 2018001199 A1 CL2018001199 A1 CL 2018001199A1
Authority
CL
Chile
Prior art keywords
formula
tenofovir
infeccion
emtricitabina
alafenamida
Prior art date
Application number
CL2018001199A
Other languages
English (en)
Inventor
Benjamin Micah Collman
Lei Hong
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018001199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2018001199A1 publication Critical patent/CL2018001199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una forma de dosificación oral sólida, que comprende un compuesto de Fórmula I o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de la misma, y emtricitabina o una sal farmacéuticamente aceptable de la misma.
CL2018001199A 2015-11-09 2018-05-03 Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana CL2018001199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09
US201662399999P 2016-09-26 2016-09-26

Publications (1)

Publication Number Publication Date
CL2018001199A1 true CL2018001199A1 (es) 2018-09-28

Family

ID=57346085

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001199A CL2018001199A1 (es) 2015-11-09 2018-05-03 Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana

Country Status (27)

Country Link
US (3) US10548846B2 (es)
EP (2) EP3632415A1 (es)
JP (1) JP6621933B2 (es)
KR (4) KR102153996B1 (es)
CN (2) CN108348473B (es)
AU (2) AU2016354007C9 (es)
BR (1) BR102016026127A2 (es)
CA (1) CA2948021C (es)
CL (1) CL2018001199A1 (es)
CO (1) CO2018004776A2 (es)
CR (1) CR20180253A (es)
EA (1) EA201890654A1 (es)
EC (1) ECSP18033723A (es)
ES (1) ES2757560T3 (es)
IL (1) IL258459A (es)
MX (1) MX2018005729A (es)
NZ (1) NZ741957A (es)
PE (1) PE20181207A1 (es)
PH (1) PH12018501001A1 (es)
PL (1) PL3346995T3 (es)
PT (1) PT3346995T (es)
SG (1) SG11201802983TA (es)
SI (1) SI3346995T1 (es)
SV (1) SV2018005682A (es)
TW (2) TWI737647B (es)
UY (1) UY36981A (es)
WO (1) WO2017083304A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CA2948021C (en) * 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP2020530024A (ja) * 2017-08-09 2020-10-15 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及び治療
US20200246351A1 (en) * 2017-08-09 2020-08-06 Viiv Healthcare Company Combinations and uses and treatments thereof
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US20210393631A1 (en) * 2018-09-19 2021-12-23 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN119174736A (zh) * 2024-09-09 2024-12-24 安徽贝克生物制药有限公司 一种三联复方片及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331208A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7517532B2 (en) 2002-09-11 2009-04-14 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
EP3187225B1 (en) 2005-04-28 2022-01-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SG170795A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2008043829A2 (en) 2006-10-14 2008-04-17 Boehringer Ingelheim International Gmbh Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
HRP20151009T1 (hr) 2009-02-06 2015-10-23 Gilead Sciences, Inc. Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
CA2818097C (en) * 2010-11-19 2019-07-30 Janssen R & D Ireland Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
PT2729130T (pt) 2011-07-07 2017-12-13 Gilead Sciences Inc Formulações de combinação de darunavir
TWI516499B (zh) 2011-08-16 2016-01-11 吉李德科學股份有限公司 泰諾福韋（ｔｅｎｏｆｏｖｉｒ）亞拉芬醯胺（ａｌａｆｅｎａｍｉｄｅ）之半反式丁烯二酸鹽
EA026138B1 (ru) * 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (es) * 2013-07-12 2018-07-21
JP2016528240A (ja) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
PE20180411A1 (es) 2015-06-30 2018-03-01 Gilead Sciences Inc Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
CA2948021C (en) 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
KR102100436B1 (ko) 2018-10-30 2020-04-13 울산과학기술원 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법

Also Published As

Publication number Publication date
CR20180253A (es) 2018-07-16
KR20200106222A (ko) 2020-09-11
AU2016354007C9 (en) 2020-10-01
CN108348473A (zh) 2018-07-31
KR20230015512A (ko) 2023-01-31
CN108348473B (zh) 2021-06-18
NZ741957A (en) 2019-04-26
UY36981A (es) 2017-06-30
JP6621933B2 (ja) 2019-12-18
PE20181207A1 (es) 2018-07-23
KR102153996B1 (ko) 2020-09-09
EP3632415A1 (en) 2020-04-08
KR20180067702A (ko) 2018-06-20
TWI737647B (zh) 2021-09-01
EP3346995B1 (en) 2019-08-28
EA201890654A1 (ru) 2018-10-31
PL3346995T3 (pl) 2020-03-31
CO2018004776A2 (es) 2018-06-20
KR102606625B1 (ko) 2023-11-27
US20220378798A1 (en) 2022-12-01
PT3346995T (pt) 2019-11-22
JP2018532811A (ja) 2018-11-08
WO2017083304A1 (en) 2017-05-18
PH12018501001A1 (en) 2018-12-17
AU2020200995A1 (en) 2020-02-27
SG11201802983TA (en) 2018-05-30
HK1256093A1 (zh) 2019-09-13
AU2020200995B9 (en) 2022-04-28
US11744802B2 (en) 2023-09-05
HK1256903A1 (en) 2019-10-04
AU2016354007B2 (en) 2019-11-14
ECSP18033723A (es) 2018-05-31
KR20240095320A (ko) 2024-06-25
AU2020200995B2 (en) 2022-04-07
BR102016026127A2 (pt) 2017-05-16
US20170189337A1 (en) 2017-07-06
SV2018005682A (es) 2018-08-15
CN113546052A (zh) 2021-10-26
EP3346995A1 (en) 2018-07-18
AU2016354007A8 (en) 2018-06-14
MX2018005729A (es) 2018-08-09
AU2016354007A1 (en) 2018-05-10
IL258459A (en) 2018-05-31
CA2948021A1 (en) 2017-05-09
CA2948021C (en) 2024-06-18
US10548846B2 (en) 2020-02-04
TW202220660A (zh) 2022-06-01
WO2017083304A8 (en) 2018-04-19
TW201726139A (zh) 2017-08-01
SI3346995T1 (sl) 2019-11-29
US20210052502A1 (en) 2021-02-25
AU2016354007C1 (en) 2020-09-10
ES2757560T3 (es) 2020-04-29

Similar Documents

Publication Publication Date Title
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
IL250196A0 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
UY36275A (es) Compuestos aminopirimidinilo
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2017001512A (es) Compuestos activos hacia bromodominios.
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
ES2571452T3 (es) Compuesto antagonista de leucotrieno B4
MX2016005161A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
UA100710U (xx) Застосування капсул "фітовенол" як гепатопротекторного засобу